৳ 2,500/unit
Pack: ৳ 2,500
৳ 2,500/unit
Pack: ৳ 2,500
At a glance
Human Papillomavirus Bivalent is indicated for women aged 9-45 years for preventing cervical cancer and other diseases caused by HPV types 16 and 18.
Indications
- Cervical cancer
- Cervical intraepithelial neoplasia Grade 2 or 3 (CIN2/3)
- Adenocarcinoma in-situ (AIS)
- Cervical intraepithelial neoplasia Grade 1 (CIN1)
- Persistent infections of HPV types 16 and/or 18
Pharmacology
HPV Bivalent vaccine contains L1 proteins of HPV types 16 and 18 produced by recombinant DNA technology, which form virus-like particles (VLPs). These VLPs act as antigens and generate HPV-specific antibodies in the body.
Dosage
Adult Dose (9-45 years, Female):
- 3 doses (0.5 ml each) intramuscular: 0, 1 and 6 months
- Flexible schedule: 2nd dose at 1-2 months, 3rd dose at 5-8 months
Child Dose (9-14 years, Female):
- 2 doses (0.5 ml each) intramuscular: 0 and 6 months (minimum 5 months interval)
Side effects
Common Local Reactions:
- Pain, redness, swelling at injection site
Common Systemic Reactions:
- Fever (≥37.1°C)
- Headache, fatigue, cough, muscle pain
- Nausea, diarrhea, dizziness, vomiting
Occasional Reactions:
- Hypersensitivity, allergic dermatitis, rash, pruritus
Use in pregnancy
Use in Pregnancy: Avoid vaccination during pregnancy. Animal studies show no direct or indirect adverse effects. If pregnant or planning pregnancy, postpone vaccination and administer after pregnancy.
Precautions & warnings
Precautions:
- Vaccination cannot replace routine cervical cancer screening
- Review medical history before vaccination
- Prepare emergency medical measures for allergic reactions
- Observe for at least 30 minutes after each injection (to prevent syncope)
- Postpone vaccination in acute febrile illness
- Use with caution in thrombocytopenia or coagulation disorders
Overdose effects
No information on overdose.
Storage conditions
Store at +2°C to +8°C. Transport also at +2°C to +8°C. Do not freeze. Protect from light.